Avinger Inc
NASDAQ:AVGR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Avinger Inc
Net Change in Cash
Avinger Inc
Net Change in Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Avinger Inc
NASDAQ:AVGR
|
Net Change in Cash
-$2.8m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Net Change in Cash
$1.5B
|
CAGR 3-Years
87%
|
CAGR 5-Years
0%
|
CAGR 10-Years
27%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Net Change in Cash
-$119.3m
|
CAGR 3-Years
9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Stryker Corp
NYSE:SYK
|
Net Change in Cash
$359m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-14%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Net Change in Cash
$906m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
24%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Net Change in Cash
$1.3B
|
CAGR 3-Years
66%
|
CAGR 5-Years
24%
|
CAGR 10-Years
28%
|
|
Avinger Inc
Glance View
Avinger, Inc. is a commercial-stage medical device company, which engages in the designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease. The company is headquartered in Redwood City, California and currently employs 74 full-time employees. The company went IPO on 2015-01-30. The firm designs, manufactures, and sells real-time, image-guided, minimally invasive catheter-based systems that are used by physicians to treat patients with peripheral artery disease (PAD). Its image-guided Lumivascular platform includes the Lightbox real-time imaging console, the Ocelot family of catheters, which are image-guided catheters designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (CTO), and the Pantheris family of catheters, its image-guided atherectomy family of catheters designed to allow physicians to remove arterial plaque in PAD patients. Its Pantheris is a single-use product and provides physicians with the ability to see a cross-sectional view of the peripheral artery to guide the removal of blockages throughout the procedure. The company has also developed a line extension of its Pantheris image-guided atherectomy platform, Pantheris SV (Small Vessel).
See Also
What is Avinger Inc's Net Change in Cash?
Net Change in Cash
-2.8m
USD
Based on the financial report for Sep 30, 2024, Avinger Inc's Net Change in Cash amounts to -2.8m USD.
What is Avinger Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 3Y
-8%
Over the last year, the Net Change in Cash growth was 67%. The average annual Net Change in Cash growth rates for Avinger Inc have been -8% over the past three years .